Back to results
US 2019/0169134 A1Published application
Novel class of quinolone heterocyclic aromatic molecules for cancer treatment
AssigneeRenoTarget Therapeutics, Inc.
InventorsJujun Wang, Allen Tsao
Life of this patent
Estimating the term…
Abstract
The invention is directed to new class of quinolone heterocyclic aromatic molecules (Renotinibs) and their use in the treatment of cancer, in particular, cancer that harbor abnormal human epidermal growth factor receptors (EGFRs) and or cancer that has abnormal DNA repair system.
Claims20
A compound having the structure of Formula I:
- wherein:
- R1 is selected from the group consisting of:
- where n is 0, 1, 2, 3, or 4;
- R2 is selected from the group consisting of:
- —H, —CH3, —OCH3, —NO2 and a halogen,
- R3 is selected from the group consisting of:
- —H, —CH3, —OCH3, and a halogen,
- R4 is selected from the group consisting of:
- —H, —CH3, —OCH3, —NO2, and a halogen,
- R5 is selected from the group consisting of:
- —H, —CH3, —OCH3, and a halogen,
- R6 is selected from the group consisting of:
- —H, and a halogen,
- R7 is selected from the group consisting of:
- —H, and a halogen,
- R8 is a halogen, and
- R9 is selected from the group consisting of:
- —H, and a halogen,
- or a pharmaceutically acceptable salt thereof.
16 more elements
Dependencies are inferred from the claim text.